The role of Pipelle® Mark II sampling in endometrial disease diagnosis

ObjectiveTo evaluate the feasibility and accuracy of Pipelle® Mark II sampling (designed for combined cytology and histology testing) in the diagnosis of endometrial disease.Materials and methodsA 97 women with abnormal uterine bleeding or intrauterine lesions on ultrasound examination underwent Pipelle® Mark II endometrial sampling, followed by diagnostic hysteroscopy. The adequacy of endometrial samples obtained for cytological and histological analysis was assessed.A correlation was established between endometrial cytology, histology and diagnostic hysteroscopy results. Where discrepancies were found, they were compared with the histological results obtained from operative hysteroscopy.ResultsThe tissue samples obtained for cytological and histological diagnoses were insufficient in 14.4% and 11.3% of patients, respectively. The opposite was found in the group of postmenopausal women (N = 52): the tissue samples for cytological and histological diagnoses were insufficient in only 3.8% and 15.4% of cases, respectively. The cytological results corroborated diagnostic hysteroscopy findings and histological results in all cases but 3 (3.6%).Only two cases of endometrial carcinoma were reported in this group of patients, and they were both detected by all three methods.The rate of false positives with endometrial cytological sampling was 3.6%. There were no false negatives.ConclusionPipelle® Mark II endometrial sampling is feasible. It provides adequate samples for histological and/or cytological analysis and reliable results. It reduces the rate of false negative results for endometrial cancer. Pipelle® Mark II sampling is particularly useful in postmenopausal women and in women with endometrial atrophy. Other larger studies are necessary to evaluate the efficiency of Pipelle Mark II.